Longevity Briefing
A curated daily readout of the science, companies, capital flows, and policy moves shaping longevity.
KEANAISSANCE convenes a tightly curated group of founders, investors, clinicians, and operators in a setting designed to accelerate execution in the longevity economy. By removing the audience layer and focusing on decision-makers with direct agency, it creates an environment where capital, science, and delivery can align more quickly. The result is not just discussion, but a higher probability of real partnerships, capital deployment, and tangible progress.
Trending Now
Based on last 48h engagement
More from Masters of Longevity
On April 8, the streets of Madrid were not the scene of an ordinary protest. Citizens, scientists, entrepreneurs, and healthcare professionals gathered for the Longevity March, a global mobilization that connected Madrid simultaneously with major cities such as Brussels, London, Paris, and Berlin in Europe; Caracas, Mexico City, and San Francisco in the Americas; and Abu Dhabi and Tel Aviv in the Middle East, even during the current war in the region. The message was clear and urgent: aging must be treated as a global political and scientific priority.
The gut microbiome has become a scientific and public fascination, with new studies and health claims emerging daily. While diet is often cited as the key factor shaping gut bacteria, research suggests a far more complex picture. With over 200 variables influencing an individual’s microbiome and only a fraction of its variability explained, the idea of a universally “healthy” gut remains elusive. Popular microbiome tests and interventions may not tell the whole story – especially when stool samples only offer a partial snapshot of the vast intestinal ecosystem. This article explores the intricate relationship between diet, microbiome diversity, and health, challenging common assumptions and highlighting the unanswered questions in this rapidly evolving field.
The Swiss healthcare system is frequently cited as one of the most robust, high-quality, and accessible systems in the world. However, a closer examination of its financial architecture reveals a system fundamentally misaligned with the emerging paradigm of longevity and preventive health. It’s a system optimized for “Sick Care” – the management of acute pathology and established chronic disease – but structurally fails to preserve health capital. This report dissects the structural and economic forces behind this dynamic and explores what would need to change to enable a transition toward a prevention- and longevity-driven healthcare system.
A ResearchAndMarkets report profiles more than 80 companies and over 100 RNA therapy candidates, covering coding mRNA and non-coding modalities across development stages and administration routes.
Why it matters The report provides a consolidated view of the global RNA therapeutics landscape, useful for investors, founders, and researchers assessing market.
Researchers used transgenic mice with human antibody genes to generate monoclonal antibodies against EBV gp350 and gp42, with one antibody fully preventing infection in humanized lab models.
Why it matters Epstein-Barr virus infects the vast majority of people and is linked to cancers and chronic disease.
Examines whether principles of plant non-host resistance can inform a theoretical non-cancer environment in animals and outlines molecular strategies to enhance organism-level anti-cancer defenses.
Why it matters Offers a conceptual shift from targeting individual tumors to engineering organism-level resistance, which could open new avenues for prevention.
Transient cardiac overexpression of P-glycoprotein via lipid nanoparticle mRNA reduced intracellular doxorubicin, improved survival, and restored cardiac function in mouse and pig models of chemotherapy-induced cardiotoxicity.
Why it matters This mRNA LNP approach offers a novel cardioprotective tactic for chemo-induced heart damage, with efficacy shown in small and large animals.
